Insider · CIK 0002017374
Garth Lees-Rolfe
Files at IKT (Inhibikase Therapeutics, Inc.). First filing -, latest -.
Garth Lees-Rolfe files SEC Form 4 as CFO at IKT (Inhibikase Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Garth Lees-Rolfe has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,834 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +5,834 | $0.00 | $0 | 5,834 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -90,000 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Jan 22, 2025 |
| Jan 3, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +470,861 | $0.00 | $0 | 470,861 | Jan 7, 2025 |
| Jan 3, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +235,383 | $0.00 | $0 | 235,383 | Jan 7, 2025 |
| Jan 3, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +432,853 | $0.00 | $0 | 432,853 | Jan 7, 2025 |
Questions about Garth Lees-Rolfe
Answered from the filings on this page, as of the latest one.
Is Garth Lees-Rolfe buying or selling?
Garth Lees-Rolfe has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Garth Lees-Rolfe's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Garth Lees-Rolfe has 0.
Where does Garth Lees-Rolfe file Form 4?
Garth Lees-Rolfe has filed Form 4 at IKT (Inhibikase Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.